HLA-Cw6 status predicts efficacy of biologic treatments in psoriasis patients
Wayne P Gulliver1,2*, Heather Young1, Susanne Gulliver4 and Shane Randell1,2
1Newlab Clinical Research, St. John’s, NL, Canada
2Department of Medicine, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL, Canada

Abstract
Over the past decade, biologic therapies have been developed to treat auto-inflammatory conditions such as psoriasis. They have the advantage of better target specificity than traditional systems like methotrexate and cyclosporine and therefore significantly reduce side-effects and toxicity associated with widespread systemic treatments. It has been suggested that the efficacy of biologics used in the treatment of psoriasis may be related with HLA-Cw6 status. Using HLA-Cw6 as a biomarker would therefore provide an advantage in the selection of a biologic agent for successful treatment based on a patient’s genetic makeup and thus allowing us to use HLA-Cw6 to individualize therapy for patients with moderate-to-severe psoriasis. In the present study, the HLA-Cw6 status was determined for psoriasis patients previously treated with etanercept, adalimumab, efalizumab, infliximab or ustekinumab. The success or failure rates of the biologic treatments were compared for patients with and without the HLA-Cw6 allele. The HLA-Cw6 status was significantly associated to the treatment outcomes for biologics efalizumab (no longer on the market), infliximab and ustekinumab; but not etanercept or adalimumab. These results support the use of HLA-Cw6 status as a biomarker for biologic treatment in moderate-to-severe psoriasis patients.

Introduction
Psoriasis vulgaris is a chronic inflammatory skin disease that presents as scaly plaques on the skin [1] and is estimated to affect 2-3% of the population. While the specific etiology remains elusive, studies have suggested a mechanism stimulating inappropriate immune-mediated and inflammatory responses. It is hypothesised that the antimicrobial peptide LL-37 and HLA-Cw6 may play a role in the pathogenesis of psoriasis [2,3]. LL-37 is overexpressed in keratinocytes in psoriasis and via HLA-Cw6 is presented as the auto antigen to CD-8 T-cell cells and to dendritic cells leading to the production of cytokine-infiltrationg an inflammatory cascade in psoriasis patients [2]. Psoriatic lesions are characterized by keratinocyte hyper-proliferation and inflammation resulting from T-cell differentiation and abundance of pro-inflammatory cytokines such as interferon-gamma (IFNγ), tumour necrosis factor alpha (TNFa), interleukin (IL) 12 and IL-23 [1,4,5] and is mediated via LL-37 and HLA-Cw6 [2].

Psoriasis pathogenesis is multi-factorial, but includes a significant genetic component; first-degree relatives are 4-6 times more likely to develop psoriasis [5] and monozygotic twins are both affected more frequently than dizygotic twins [6]. Susceptibility studies have identified candidate genes in the PSORS1 region of chromosome 6, most significantly the HLA-C gene in the region of the major histocompatibility complex (MHC) [7,8]. The HLA-C isotype HLA-Cw6 is strongly associated with the development of psoriasis and with a more severe form presenting at a younger age [8-11].

The association of psoriasis with HLA was demonstrated in 1980 with the strongest association seen in the HLA-Cw6 allele [9]. Research from 1993 suggests that the HLA-Cw6 allele is an indicator for susceptibility for psoriasis development as well as early age of onset in HLA-Cw6 positive psoriasis patients [8]. Individuals with late onset of disease and are HLA-Cw6 positive tend to have milder severity [12].

The association appears strong and is found in anywhere from 40-80% of cases [9], however other genes nearby may play a role that also contribute to the development of psoriasis. There are other gene-disease associations that are documented indicating stronger causality such as HLA-B27 and ankylosing spondylitis (AS) where the HLA-B27 allele is seen in up to 100% of AS patients [13]. Even though the relationship between psoriasis and HLA-Cw6 may not be as definitive as HLA-B27 and AS, the association has consistently been seen in psoriasis patients.

In the past decade, biologic therapies have been introduced and embraced as an ideal treatment option as they generally have high efficacy and a favourable benefit-to-risk ratio. New developments in the pharmacogenetics of psoriasis could help better predict the likelihood of response to biologic therapies in moderate to severe psoriasis patients using HLA-Cw6 as a marker [2].

Materials and methods
Psoriasis patients treated with one of five biologics were selected from the Newfoundland and Labrador founder population and grouped as being either responsive or non-responsive to biological treatment. Patients were then tested for the HLA-Cw6 single nucleotide polymorphism (SNP).

Blood samples were collected in sterile 10 mL tubes containing EDTA. Isolation and purification of DNA was performed using either Promega Wizard Genomic DNA Purification kit or AutoGen Mini80 QuickGene DNA Whole Blood Kit, as per the manufacturer’s instructions.

Correspondence to: Dr. Wayne Gulliver, Newlab Clinical Research, 187 Lemarchant Road, St. John’s, NL, Canada, A1C 2H5, Tel: 1-709-753-5520; E-mail: WGulliver@newlabresearch.com

Received: December 01, 2015; Accepted: December 16, 2015; Published: December 19, 2015
instructions. Resulting DNA was diluted to 30 ng/µL for use in polymerase chain reaction (PCR).

PCR was performed using the Olerup SSP HLA-Cw*06 amplification kit (Stockholm, Sweden), as per the manufacturer's instructions. A solution was created using DNA, sterile water, and master mix containing Taq polymerase, nucleotides, and divalent ions. The solution was mixed and 10 µL aliquoted into tubes containing dried primer pairs for both control and test sequences. The tubes were placed in the thermocycler and amplified for 10 cycles at 94°C for 10 seconds to denature and 65°C for 60 seconds to anneal and extend for the last 20 cycles. DNA was amplified for 10 cycles at 94°C for 10 seconds to denature, 61°C for 50 seconds to anneal, 72°C for 30 seconds to extend, then held at 4°C. Amplification products and a DNA ladder were loaded into a 2% agarose gel made/run using 0.5X TE buffer at 8-10 volts/cm for 15-20 minutes. The gel was then transferred to a Bio-imager, a picture taken under UV light, and genotype status recorded.

Genotype data was then used to further subgroup patients in the responsive and non-responsive groups as being HLA-Cw6+ or HLA-Cw6-. Resulting data was put in a contingency table, the odds ratio calculated, and significance determined using Fisher’s exact test for two-tailed samples. Separate contingency tables were also made for each of the biologics: etanercept, adalimumab, efalizumab, infliximab, and ustekinumab.

**Results**

Figure 1 (Efficacy of Different Biologics on HLC-cw6 Positive and Negative Psoriasis Patients) can be seen below. Figure 1a compares the efficacy of all biologics on patients that are HLA-Cw6 positive or negative. Figures 1b, 1c, 1d, 1e, and 1f compare the genotype status on efficacy for etanercept, adalimumab, efalizumab, infliximab, and ustekinumab, respectively.

Biologics in general were found to be significantly more effective in patients that are HLA-Cw6 positive (OR=4.427, p=0.0005). Of the five biologic treatments tested, infliximab, ustekinumab, and efalizumab demonstrated significant differences in efficacy between HLA-Cw6 positive and negative patients (p=0.0391, p=0.0112, and p=0.0124, respectively). The efficacies of all three biologics were significantly higher in HLA-Cw6 positive patients (OR=8, OR=21, OR=23). There was no significance difference in symptom resolution between HLA-Cw6 positive and negative patients treated with etanercept or adalimumab (OR=1, p=1.0000; OR=1.2, p=1.0000, respectively).

In order to increase the statistical power of analysis, our data was pooled with data from Talamonti et al., [14] and Costanzo et al., [15] for patients taking etanercept, ustekinumab, and efalizumab. Data was re-analyzed and is presented in Figure 2 (Efficacy of Etanercept, Ustekinumab, and Efalizumab on HLA-Cw6 Positive and Negative Psoriasis Patients). The efficacy of ustekinumab and efalizumab were again significantly higher in HLA-Cw6 positive patients (p=0.0001 and p=0.0101 respectively). Etanercept demonstrated a non-significant trend of increased efficacy in HLA-Cw6 negative patients.

![Figure 1](image-url)
Discussion

Psoriasis has been observed have bimodal peaks of age of onset; the first occurring around the age of 20 and the second occurring around the age of 50 [6]. In non-pustular psoriasis, two types can be independently observed; Type I and Type II. Type I psoriasis often encompasses positive family history, linkage disequilibrium for human leucocyte antigens (HLAs) Cw6, B13 and Bw57 as well as an early onset (the first peak) [6]. Type II presents around the second peak (age 50-60) and tends to have higher with Cw2 and B27 [16]. Psoriasis has been linked to numerous comorbidities such as cardiovascular disease, diabetes, hypertension, obesity and dyslipidemia [17]. Associations with multiple traditional cardiovascular risk factors (such as smoking, obesity, stress and chronic inflammation) are documented and may lead to an increase in risk of mortality in patients admitted to the hospital at least once for their skin by 50% [18,19].

The association between psoriasis and HLA-Cw6 was first documented in the 1980s and since then this association has been observed consistently as having the highest association with psoriasis and representing the most obvious biomarker candidate [8,20]. Psoriasis has been difficult to map to a specific locus, likely due to the number of factors involved in dysregulation/inflammation and the multiple gene loci they represent [16]. The identification of other candidate genes likely represents a separate pathogenic pathway leading to psoriasis in the non-HLA-Cw6 patients. The HLA-Cw6 status has long been associated with early-onset psoriasis and severe symptoms [8,21]. Other studies have reported psoriasis associations with HLA-B and non-HLA genes (such as HCR and CDSN) within the MHC but independence from HLA-C has yet to be established. Still, HLA-C is well established as a psoriasis gene with HLA-Cw6 positivity leading to an increase in risk of developing psoriasis as part of an integrated complex involving skin barrier function signalling [20]. It is believed that HLA-Cw6 positivity is linked to an early age of onset of psoriasis and a paediatric study using an East Indian population [10] found that Guttate psoriasis, scalp involvement and severe disease all corresponded to HLA-Cw6 positivity in these children. In this study, we present new evidence to support the use of HLA-Cw6 status as a biomarker for biologic treatment selection. Traditionally, specific biologics were prescribed on a trial-and-error basis. Studies have also shown that PGA 0/1 response to a biologic that is used as a second line therapy is lower than when it is used as a first line therapy, making the treatment significantly less cost effective [22,23]. These results demonstrate the predictive value of HLA-Cw6 genotyping on the success of biologic treatments. Commercially available kits are already available for HLA-Cw6 genotyping and are significantly more cost effective than an unsuccessful round of biologic treatment and significantly reduce the unnecessary risk of a trial-and-error treatment approach.

Conclusion

HLA-Cw6 is believed to be a susceptibility gene for Psoriasis vulgaris. Biologic therapies are proving to be an effective treatment option with a favourable benefit-to-risk ratio. It has been rather difficult to choose which biologic therapy to use which is seen in the present treatment paradigm of the trial-and-error approach. However recent literature, as well as the data presented in this study, suggests that HLA-Cw6 positivity may be associated with increased efficacy in certain biologic therapies. Thus the approach using individualized medicine is likely to result in a multitude of benefits including: more timely control of the disease and timely improvements in quality of life and productivity; as well as less switching from one biologic therapy to another, and improvements in the cost effectiveness of biologic therapies for the treatment of moderate-to-severe psoriasis.

Figure 2. Efficacy of Etanercept, Ustekinumab, and Efalizumab on HLA-Cw6 Positive and Negative Psoriasis Patients.
